|
1
|
Rafieian-Kopaei M, Setorki M, Doudi M,
Baradaran A and Nasri H: Atherosclerosis: Process, indicators, risk
factors and new hopes. Int J Prev Med. 5:927–946. 2014.PubMed/NCBI
|
|
2
|
Fabriek BO, Dijkstra CD and van den Berg
TK: The macrophage scavenger receptor CD163. Immunobiology.
210:153–160. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Aristoteli LP, Møller HJ, Bailey B,
Moestrup SK and Kritharides L: The monocytic lineage specific
soluble CD163 is a plasma marker of coronary atherosclerosis.
Atherosclerosis. 184:342–347. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Lin J, Kakkar V and Lu X: Impact of MCP-1
in atherosclerosis. Curr Pharm Des. 20:4580–4588. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Ylä-Herttuala S, Lipton BA, Rosenfeld ME,
Särkioja T, Yoshimura T, Leonard EJ, Witztum JL and Steinberg D:
Expression of monocyte chemoattractant protein 1 in macrophage-rich
areas of human and rabbit atherosclerotic lesions. Proc Natl Acad
Sci USA. 88:5252–5256. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Blanco-Colio LM, Tuñón J, Martín-Ventura
JL and Egido J: Anti-inflammatory and immunomodulatory effects of
statins. Kidney Int. 63:12–23. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Risovic V, Man D, Sivak O, Lee SD and
Wasan KM: Assessing lipid lowering and plasma cholesteryl ester
transfer protein activity of simvastatin following administration
to rabbits fed a high fat/cholesterol diet. Drug Dev Ind Pharm.
32:609–615. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Zhang YH, Zhang Y, Li J, Tong WX and Xu
FQ: Protective effects of Xiongshao Capsule () on anti-inflammatory
function of high-density lipoprotein in atherosclerosis rabbit
model. Chin J Integr Med. 10:102015.
|
|
9
|
Djerrou Z: Anti-hypercholesterolemic
effect of Pistacia lentiscus fatty oil in egg yolk-fed rabbits: A
comparative study with simvastatin. Chin J Nat Med. 12:561–566.
2014.PubMed/NCBI
|
|
10
|
Rasmusen C, Moinard C, Martin C, Tricottet
V, Cynober L and Couderc R: L-arginine plus atorvastatin for
prevention of atheroma formation in genetically
hypercholesterolaemic rabbits. Br J Nutr. 97:1083–1089. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Yanni AE, Yatzidis HA, Kavantzas NG,
Agapitos EV, Perrea DN and Karayannacos PE: Dietary L-aspartate and
L-glutamate inhibit fatty streak initiation in cholesterol-fed
rabbit. Nutr Metab Cardiovasc Dis. 13:80–86. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Franci O, Amici A, Margarit R, Merendino N
and Piccolella E: Influence of thermal and dietary stress on immune
response of rabbits. J Anim Sci. 74:1523–1529. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Cook DL, Mills LM and Green DM: The
mechanism of alloxan protection in experimental atherosclerosis. J
Exp Med. 99:119–124. 1954. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Kamimura R, Suzuki S, Sakamoto H, Miura N,
Misumi K and Miyahara K: Development of atherosclerotic lesions in
cholesterol-loaded rabbits. Exp Anim. 48:1–7. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Verma DR and Brinton EA: Management of
hypercholesterolemia for prevention of atherosclerotic
cardiovascular disease: Focus on the potential role of recombinant
anti-PCSK9 monoclonal antibodies. Rev Cardiovasc Med. 15:86–101;
quiz 101. 2014.PubMed/NCBI
|
|
16
|
Roberts WC: Twenty questions on
atherosclerosis. Proc (Bayl Univ Med Cent). 13:139–143.
2000.PubMed/NCBI
|
|
17
|
Roh E, Ko SH, Kwon HS, Kim NH, Kim JH, Kim
CS, Song KH, Won JC, Kim DJ, Choi SH, et al: Taskforce Team of
Diabetes Fact Sheet of the Korean Diabetes Association: Prevalence
and Management of Dyslipidemia in Korea: Korea National Health and
Nutrition Examination Survey during 1998 to 2010. Diabetes Metab J.
37:433–449. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Korou LM, Agrogiannis G, Koros C, Kitraki
E, Vlachos IS, Tzanetakou I, Karatzas T, Pergialiotis V,
Dimitroulis D and Perrea DN: Impact of N-acetylcysteine and sesame
oil on lipid metabolism and hypothalamic-pituitary-adrenal axis
homeostasis in middle-aged hypercholesterolemic mice. Sci Rep.
4:68062014. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Kapourchali FR, Surendiran G, Chen L, Uitz
E, Bahadori B and Moghadasian MH: Animal models of atherosclerosis.
World J Clin Cases. 2:126–132. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Dornas WC, Oliveira TT, Augusto LE and
Nagem TJ: Experimental atherosclerosis in rabbits. Arq Bras
Cardiol. 95:272–278. 2010.(In Portuguese). View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Yanni AE: The laboratory rabbit: An animal
model of atherosclerosis research. Lab Anim. 38:246–256. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Profumo E, Buttari B, Saso L and Rigano R:
Pleiotropic effects of statins in atherosclerotic disease: Focus on
the antioxidant activity of atorvastatin. Curr Top Med Chem.
14:2542–2551. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Tousoulis D, Oikonomou E, Economou EK,
Crea F and Kaski JC: Inflammatory cytokines in atherosclerosis:
Current therapeutic approaches. Eur Heart J. 37:1723–1732. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
März W, Scharnagl H, Gouni-Berthold I,
Silbernagel G, Dressel A, Grammer TB, Landmesser U, Dieplinger H,
Windler E and Laufs U: LDL-Cholesterol: Standards of Treatment
2016: A German Perspective. Am J Cardiovasc Drugs. 16:323–336.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Ahn CH and Choi SH: New drugs for treating
dyslipidemia: Beyond statins. Diabetes Metab J. 39:87–94. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Toth PP: Drug treatment of
hyperlipidaemia: A guide to the rational use of lipid-lowering
drugs. Drugs. 70:1363–1379. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Toth PP and Davidson MH: Simvastatin plus
ezetimibe: Combination therapy for the management of dyslipidaemia.
Expert Opin Pharmacother. 6:131–139. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Satoh M, Takahashi Y, Tabuchi T, Minami Y,
Tamada M, Takahashi K, Itoh T, Morino Y and Nakamura M: Cellular
and molecular mechanisms of statins: An update on pleiotropic
effects. Clin Sci (Lond). 129:93–105. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Tissier F, Mallem Y, Goanvec C, Didier R,
Aubry T, Bourgeois N, Desfontis JC, Dubreuil M, Le Grand Y,
Mansourati J, et al: A non-hypocholesterolemic atorvastatin
treatment improves vessel elasticity by acting on elastin
composition in WHHL rabbits. Atherosclerosis. 251:70–77. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Lin CP, Huang PH, Lai CF, Chen JW, Lin SJ
and Chen JS: Simvastatin Attenuates Oxidative Stress, NF-κB
Activation, and Artery Calcification in LDLR-/- Mice Fed with High
Fat Diet via Down-regulation of Tumor Necrosis Factor-α and TNF
Receptor 1. PLoS One. 10:e01436862015. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Ludman A, Venugopal V, Yellon DM and
Hausenloy DJ: Statins and cardioprotection-more than just lipid
lowering? Pharmacol Ther. 122:30–43. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Xian-Yu JB, Feng JF, Chen YC and Yang YW:
Effects of simvastatin and atorvastatin on biochemical and
hematological markers in patients with risk of cardiovascular
diseases. Int J Clin Exp Med. 8:13983–13989. 2015.PubMed/NCBI
|
|
33
|
Andreadou I, Farmakis D, Prokovas E,
Sigala F, Zoga A, Spyridaki K, Papalois A, Papapetropoulos A,
Anastasiou-Nana M, Kremastinos DT, et al: Short-term statin
administration in hypercholesterolaemic rabbits resistant to
postconditioning: Effects on infarct size, endothelial nitric oxide
synthase, and nitro-oxidative stress. Cardiovasc Res. 94:501–509.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Iliodromitis EK, Andreadou I, Prokovas E,
Zoga A, Farmakis D, Fotopoulou T, Ioannidis K, Paraskevaidis IA and
Kremastinos DT: Simvastatin in contrast to postconditioning reduces
infarct size in hyperlipidemic rabbits: Possible role of
oxidative/nitrosative stress attenuation. Basic Res Cardiol.
105:193–203. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Stein EA, Lane M and Laskarzewski P:
Comparison of statins in hypertriglyceridemia. Am J Cardiol.
81(4A): 66B–69B. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Brinton EA: Management of
hypertriglyceridemia for prevention of atherosclerotic
cardiovascular disease. Cardiol Clin. 33:309–323. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Ross R: Atherosclerosis - an inflammatory
disease. N Engl J Med. 340:115–126. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Deshmane SL, Kremlev S, Amini S and Sawaya
BE: Monocyte chemoattractant protein-1 (MCP-1): An overview. J
Interferon Cytokine Res. 29:313–326. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Takahashi K, Takeya M and Sakashita N:
Multifunctional roles of macrophages in the development and
progression of atherosclerosis in humans and experimental animals.
Med Electron Microsc. 35:179–203. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Chen YL, Chang YJ and Jiang MJ: Monocyte
chemotactic protein-1 gene and protein expression in atherogenesis
of hypercholesterolemic rabbits. Atherosclerosis. 143:115–123.
1999. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Burdo TH, Lo J, Abbara S, Wei J, DeLelys
ME, Preffer F, Rosenberg ES, Williams KC and Grinspoon S: Soluble
CD163, a novel marker of activated macrophages, is elevated and
associated with noncalcified coronary plaque in HIV-infected
patients. J Infect Dis. 204:1227–1236. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
McKibben RA, Margolick JB, Grinspoon S, Li
X, Palella FJ Jr, Kingsley LA, Witt MD, George RT, Jacobson LP,
Budoff M, et al: Elevated levels of monocyte activation markers are
associated with subclinical atherosclerosis in men with and those
without HIV infection. J Infect Dis. 211:1219–1228. 2015.PubMed/NCBI
|
|
43
|
Calderon RM, Cubeddu LX, Goldberg RB and
Schiff ER: Statins in the treatment of dyslipidemia in the presence
of elevated liver aminotransferase levels: A therapeutic dilemma.
Mayo Clin Proc. 85:349–356. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Landecho MF, Moncada R, Valentí V and
Frühbeck G: Cardiovascular Prevention in Obese Patients. Curr Pharm
Des. 22:222016. View Article : Google Scholar
|
|
45
|
Lim S and Eckel RH: Pharmacological
treatment and therapeutic perspectives of metabolic syndrome. Rev
Endocr Metab Disord. 15:329–341. 2014. View Article : Google Scholar : PubMed/NCBI
|
